Litigation Details for ASTRAZENECA PHARMACEUTICALS LP v. SAGENT PHARMACEUTICALS, INC. (D.N.J. 2014)
✉ Email this page to a colleague
ASTRAZENECA PHARMACEUTICALS LP v. SAGENT PHARMACEUTICALS, INC. (D.N.J. 2014)
| Docket | ⤷ Sign Up | Date Filed | 2014-09-02 |
| Court | District Court, D. New Jersey | Date Terminated | 2015-05-07 |
| Cause | 35:271 Patent Infringement | Assigned To | Renee Marie Bumb |
| Jury Demand | None | Referred To | Karen M. Williams |
| Patents | 6,774,122; 7,456,160; 8,329,680; 8,466,139 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in ASTRAZENECA PHARMACEUTICALS LP v. SAGENT PHARMACEUTICALS, INC.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for ASTRAZENECA PHARMACEUTICALS LP v. SAGENT PHARMACEUTICALS, INC. (D.N.J. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2015-03-23 | 40 | Statement for U.S. Patent Nos. 6,774,122 (“the ’122 Patent”), 7,456,160 (“the ’160 Patent”), 8,329,680 (…Publications); ’139 Patent at cover (Other Publications); ’122 Patent PH; ’160 Patent PH, ’680 Patent PH; ’139 Patent… (“the ’680 Patent”), and 8,466,139 (“the ’139 Patent”) (collectively, “the Patents-in-Suit”) in the…expiration of the Patents-in-Suit. A. The ’122 Patent The ’122 Patent includes two… term in the ’122 Patent (Exhibit A), the ’160 Patent (Exhibit B), the ’680 Patent (Exhibit C), and | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
